Table 2 Clinical outcomes at weeks 24 and 48 in the overall population (as-treated analysis)
Clinical outcome | Week 24 | Week 48 | ||||
|---|---|---|---|---|---|---|
Abatacept + MTX (n = 40) | Adalimumab + MTX (n = 40) | Estimate of difference for abatacept vs adalimumab (95% CI) | Abatacept non-switch (n = 40) | Adalimumab-to-abatacept switch (n = 40) | Estimate of difference for non-switch vs switch (95% CI) | |
ACR responses, % (95% CI) | ||||||
 ACR20 | 83 (67, 93) | 63 (46, 77) | 20 (−3, 42) | 78 (62, 89) | 75 (59, 87) | 3 (−20, 25) |
 ACR50 | 73 (56, 85) | 45 (29, 62) | 28 (5, 48) | 63 (46, 77) | 63 (46, 77) | 0 (−23, 23) |
 ACR70 | 50 (34, 66) | 30 (17, 47) | 20 (−3, 42) | 50 (34, 66) | 38 (23, 54) | 13 (−11, 35) |
DAS28 (CRP) | ||||||
 Adjusted mean change from baseline (95% CI) | −2.6 (−2.9, −2.3) m = 39 | −2.4 (−2.7, −2.1) m = 34 | −0.2 (−0.7, 0.2) | −2.7 (−3.0, −2.5) m = 36 | −2.9 (−3.2, −2.6) m = 33 | 0.1 (−0.3, 0.6) |
 Remission, % (95% CI)* | 55 (39, 71) | 30 (17, 47) | 25 (2, 46) | 48 (32, 64) | 50 (34, 66) | −3 (−25, 20) |
SDAI | ||||||
 Adjusted mean change from baseline (95% CI) | −28.2 (−30.5, −25.9) m = 39 | −26.0 (−28.4, −23.6) m = 34 | −2.2 (−5.5, 1.2) | −28.5 (−30.8, −26.2) m = 36 | −30.3 (−32.7, −27.9) m = 33 | 1.7 (−1.6, 5.1) |
 Remission, % (95% CI)†| 43 (27, 59) | 23 (11, 39) | 20 (−3, 42) | 43 (27, 59) | 28 (15, 44) | 15 (−8, 37) |
CDAI | ||||||
 Adjusted mean change from baseline (95% CI) | −27.3 (−29.6, −25.0) m = 39 | −25.0 (−27.4, −22.5) m = 35 | −2.3 (−5.7, 1.0) | −27.8 (−30.1, −25.5) m = 36 | −29.2 (−31.6, −26.8) m = 33 | 1.4 (−2.0, 4.7) |
 Remission, % (95% CI)‡ | 43 (27, 59) | 23 (11, 39) | 20 (−3, 42) | 40 (25, 57) | 30 (17, 47) | 10 (−13, 32) |